+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Prognostic determinants and treatment outcomes analysis of osteosarcoma and Ewing sarcoma of the spine

Prognostic determinants and treatment outcomes analysis of osteosarcoma and Ewing sarcoma of the spine

Spine Journal 17(5): 645-655

Osteosarcoma (OGS) and Ewing sarcoma (EWS) are the two classic primary malignant bone tumors. Due to the rarity of these tumors, evidence on demographics, survival determinants, and treatment outcomes for primary disease of the spine are limited and derived from small case series. To use population-level data to determine the epidemiology and prognostic indicators in patients with OGS and EWS of the osseous spine. Large-scale retrospective study. Patients diagnosed with OGS and EWS of the spine in the Surveillance, Epidemiology, and End Results (SEER) registry from 1973 to 2012. Overall survival (OS) and disease-specific survival (DSS). Two separate queries of the SEER registry were performed to identify patients with OGS and EWS of the osseous spine from 1973-2012. Study variables included age, sex, race, year of diagnosis, tumor size, extent of disease (EOD), and treatment with surgery and/or radiation therapy. Primary outcome was defined as OS and DSS in months. Univariate survival analysis was performed using the Kaplan-Meier method and the log-rank test. Multivariate analysis was performed using Cox proportional hazards regression models. The search identified 648 patients with primary OGS and 736 patients with primary EWS of the spine from 1973 to 2012. Mean age at diagnosis was 48.1 and 19.9 years for OGS and EWS, respectively, with OGS showing a bimodal distribution. The median OS and DSS were 1.3 and 1.7 years, respectively, for OGS, with OGS in Paget's disease having worse OS (0.7 years) relative to the mean (log-rank p=.006). The median OS and DSS for EWS were 3.9 and 4.3 years, respectively. Multivariate cox regression analysis showed that age (OS p<.001, DSS p<.001), decade of diagnosis (OS p=.049), surgical resection (OS p<.001, DSS p<.001), and EOD (OS p<.001, DSS p<.001) were independent positive prognostic indicators for spinal OGS; radiation therapy predicted worse OS (hazard ratio [HR] 1.48, confidence interval [CI] 1.05-2.10, p=.027) and DSS (HR 1.74, CI 1.13-2.66, p=.012) for OGS. For EWS, age (OS p<.001, DSS p<.001), surgical resection (OS p=.030, DSS p=.046), tumor size (OS p<.001, DSS p<.001), and EOD (OS p<.001, DSS p<.001) were independent determinants of improved survival; radiation therapy trended toward improved survival but did not achieve statistical significance for both OS (HR 0.76, CI 0.54-1.07, p=.113) and DSS (0.76, CI 0.54, 1.08, p=.126). Age, surgical resection, and EOD are key survival determinants for both OGS and EWS of the spine. Radiation therapy may be associated with worse outcomes in patients with OGS, and is of potential benefit in EWS. Overall prognosis has improved in patients with OGS of the spine over the last four decades.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 058634785

Download citation: RISBibTeXText

PMID: 27856382

DOI: 10.1016/j.spinee.2016.11.002

Related references

Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma. Cancer Genetics & Cytogenetics 120(2): 91-98, July 15, 2000

Impact of first-line treatment on outcomes of Ewing sarcoma of the spine. American Journal of Cancer Research 8(7): 1262-1272, 2018

Ewing sarcoma: prognostic criteria, outcomes and future treatment. Expert Review of Anticancer Therapy 8(4): 617-624, 2008

Prognostic factors in the treatment of Ewing's sarcoma. The Ewing's Sarcoma Study Group of the German Society of Paediatric Oncology CESS 81. RadioTherapy and Oncology 10(2): 101-110, 1987

Prognostic value of CCN3 in osteosarcoma and Ewing's sarcoma. 2007

Evaluation of prognostic factors in a tumor volume-adapted treatment strategy for localized Ewing sarcoma of bone: the CESS 86 experience. Cooperative Ewing Sarcoma Study. Medical and Pediatric Oncology 32(3): 186-195, 1999

Treatment outcomes of Japanese patients with Ewing sarcoma: differences between skeletal and extraskeletal Ewing sarcoma. Japanese Journal of Clinical Oncology 46(6): 522-528, 2017

Treatment and survival of osteosarcoma and Ewing sarcoma of the skull: a SEER database analysis. Acta Neurochirurgica 2018, 2018

Comprehensive analysis of published phase I/II clinical trials between 1990-2010 in osteosarcoma and Ewing sarcoma confirms limited outcomes and need for translational investment. Clinical Sarcoma Research 2(1): 5, 2012

Efficacy Comparison of Six Chemotherapeutic Combinations for Osteosarcoma and Ewing's Sarcoma Treatment: A Network Meta-Analysis. Journal of Cellular Biochemistry 119(1): 250-259, 2017

Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. European Journal of Cancer 41(9): 1349-1361, 2005

Prognostic significance of intratumoral neoangiogenesis in childhood osteosarcoma and Ewing sarcoma. Virchows Archiv 443(3): 331, 2003

Preclinical analysis of tasidotin HCl in Ewing's sarcoma, rhabdomyosarcoma, synovial sarcoma, and osteosarcoma. Clinical Cancer Research 13(18 Pt 1): 5446-5454, 2007

Demographic Analysis of Patients with Osteosarcoma, Chonddrosarcoma, Ewing's Sarcoma from one Sarcoma Center in Switzerland. Praxis 104(13): 673-680, 2015

Multimodal Treatment in Pelvic Ewing Sarcoma: A Prognostic Factor Analysis. Surgical Technology International 34, 2019